FDA OKs Norbrook Labs NADA for Bovine Respiratory Disease
09/22/2003
Federal Register Final rule: FDA is amending the animal drug regulations to reflect approval of a hybrid new animal drug application filed by Norbrook Laboratories, Ltd. that provides for the prescription and over-the-counter use of a 300 mg/mL oxytetracycline injectable solution for the treatment of various bacterial diseases of cattle and swine, and for the control of respiratory disease in cattle at high risk of developing bovine respiratory disease (BRD). To view this final rule, click here.
